Aranesp Sales Down As Physicians Adopt Wait-And-See Posture – Amgen
This article was originally published in The Pink Sheet Daily
Executive Summary
Nineteen percent decline in U.S. sales of the erythropoiesis-stimulating agent versus Q2 2006 is a response to labeling change, regulatory climate, Amgen exec says.
You may also be interested in...
Amgen Says 2007 Profits Will Top October Projections
California biotech cites cost-cutting measures as reason for upgraded earnings per share guidance of $4.30.
Amgen Says 2007 Profits Will Top October Projections
California biotech cites cost-cutting measures as reason for upgraded earnings per share guidance of $4.30.
Amgen Halts Construction On Manufacturing Plant In Ireland
The planned multi-product facility would have manufactured “drugs in the pipeline,” Amgen tells “The Pink Sheet” DAILY.